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Abstract 
Background: Commonly prescribed therapies in adolescent Acne vulgaris are topical 
regimens and oral therapy, with first line antibiotic tetracycline. With the evident 
increasing resistance of Propionibacterium acnes to oral tetracycline, treatment 
failures are a consequence.  
Aim: The aim of this systematic review was to evaluate the currently published data 
investigating the efficacy and side effects of treatment with oral tetracycline versus 
other commonly prescribed acne therapies. The secondary aim was to evaluate the 
treatment outcome related to propionibacterium acnes resistance to tetracycline.  
Methods: An electronic hand search was done in PubMed, Scopus and Cochrane 
Library databases. Selected studies were limited to those in the English language with 
a 10-year span ranging from 2002-2012. Search terms conducted for all 3 databases 
were “Acne vulgaris” and “Tetracycline”. Only Randomized controlled trials (RCT) 
were included to provide the highest evidence. For each study the risk of bias were 
assessed and a summary evaluation of the level of evidence (GRADE) were 
conducted.  
Findings: The search provided a total of 95 studies in which they were analysed 
meeting the predetermined eligibility criteria. In the final qualitative analysis 3 RCT 
studies were included. There were no significant differences in efficacy comparing 
topical regimens with antimicrobials versus oral tetracycline. Oral isotretinoin proved 
to have a superior efficacy compared to oral tetracycline. Adverse effects were 
predictable for each therapy and oral isotretinoin gave the most severe events.  
Interpretation: Oral tetracycline is an effective therapy in moderate to severe 
inflammatory acne. Even in the presence of resistant Propionibacterium acnes it is a 
successful treatment, most possibly relating to its anti-inflammatory fashion. Topical 
therapy with antimicrobials have similar efficacy as oral tetracycline. Although oral 
isotretinoin provides the best efficacy compared to oral tetracycline it is well known 
that it gives more adverse effects.  
Keywords: Acne vulgaris, tetracycline, systematic review 
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Introduction 
Background 
The prevalence of acne in young adults is about 80 % and not only affecting one 
persons skin, additionally it may have an impact of the person’s social life in a 
negative way. It has been shown that the assessed quality of life correlates with the 
extent of the acne lesions(1). While acne is most commonly occurring in adolescents 
it may persist to adulthood in 50 % of individuals, especially in women(2, 3). One 
fact that is emphasized by an assembly of researchers and physicians with special 
interest in acne known as the Global Alliance to Improve Outcomes in Acne group is 
the often chronicity of acne and stated by Thiboutot et al (2009)“not just a self-
limiting disorder of teenagers”(3). 
The pathogenesis of acne is multifactorial involving the pilosebacceous unit. Other 
factors that plays a part in the ensuing breakout is damp climate, psychological stress 
and chemicals in cosmetic products containing for example propylene glycol, leading 
to blockage of the comedones(4, 5).  
The most commonly used treatment for moderate to severe inflammatory acne is oral 
antibiotics, which is indicated when topical regimens do not clear the acne or when 
there is a risk of scarring and pigmentation(6, 7). According to Tan, A. W. et al 
(2005) the consequence of the prolonged overuse of antibiotics, the increase of 
resistant strains of Propionibacterium acnes (PA) leads to treatment failure(8). 
Important reason for this is the prescription of antibiotic therapy for too long periods, 
combining local and systemic antibiotics and lack of compliance(6, 7). Deciding what 
treatment one should prescribe in each case depends on the severity of the acne. 
There is no golden standard scale for acne grading. Now there is over 20 something 
severity grading scales used worldwide, not contributing to the consistency, making it 
difficult in the research to evaluate study outcomes(9).  
The known effects of tetracycline belonging to the cycline group antibiotics, which is 
the first line antibiotic used in Sweden for moderate to severe inflammatory acne, are 
both antimicrobial and anti-inflammatory.  
According to Chiou et al (2012) a hypothesis was proposed suggesting that the 
effectiveness of oral tetracyclines could be questioned though their study indicated a 
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superiority effect of the placebo therapy, being as effective as treatment with oral 
minocycline or other commonly prescribed tetracyclines(10).   
Aside from the PA increasing resistance to tetracycline, common adverse effects are 
gastrointestinal dyspepsia, photosensibility and yellowish discoloration and 
hypoplasia of the teeth enamel in children younger than 10 years of age(11, 12).  
In this systematic review the evaluation whether oral tetracycline is an effective 
treatment in acne, considering the PA resistance versus other available regimens 
generally used for the same indication is examined. Are there any trends of acne 
treatment prescription? And if, has it changed over the last years? Which regimen 
used globally is stated to have the best efficacy? 
Acne Vulgaris and its pathophysiology 
Acne is a skin disorder, which starts in adolescence with chronic inflammation 
involving the sebaceous glands in the epidermis. Sites of lesions occur most 
commonly on the face, neck and upper chest where hair follicles are dens(6). There 
are several components that together lead to manifestations of acne, such as papules, 
pustules and occasionally deep pustules and cysts that may lead to scarring of the 
skin(4). There is a proven genetic component for acne. A strong family history of 
acne is a predisposition, although there is little known about its mechanisms 
contributing to the pathogenesis of acne(13). There are four main factors that will 
come to discussion when enlightening the fundamentals to acne lesion formation: 
 Increased sebum production 
 Hypercornification of the pilosebacceous duct 
 Colonization of PA 
 Inflammation(12) 
Androgen receptors located on keratinocytes and the cells of the sebaceous gland are 
regulated by androgens from the gonads and adrenals, which in turn stimulates to 
increased sebum production and hypercornification(14). Notice there is no 
overproduction of androgens, instead there’s an amplified sensitivity for the 
androgens in the follicles of acne patients(12). There is a correlation between 
increased sebum production and the severity of acne. Microcomedones is the 
precursor of the acne lesion. Blackheads and whiteheads come from the description 
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of the comedones, indicating whether it is open and black allowing passage of sebum 
or closed and white, not permitting sebum outflow leading to inflammatory lesions. A 
follicle becomes plugged when there is an abnormal differentiation and proliferation 
of the ductal keratinocytes(4). These keratinocytes are normally shed from the 
follicular canal; instead they become lodged in the upper part forming the 
microcomedone(7). After removal of blackheads they restock after 2-6 weeks, 
denoting the cyclic growth of the comedone. There has been shown that there is a 
reduction of linoleic acid in sebum of acne patients compared to non-acne cases. 
Interestingly the level of linoleic acid came back to normal after therapy with oral 
isotretinoin (an derivative of vitamin-A) and antiandrogens. Low levels of linoleic 
acid are connected to hypercornification. Pathological production of the cytokine IL-
1-alfa by keratinocytes contributes to comedonogenesis. Other factors that regulate 
the follicle is the Epidermal Growth Factor and Tumor Growth Factor -Alfa, which 
inhibit sebum production(4). Normally living on the skin after puberty is the 
anaerobic organism propionibacteria. Propionibacterium acnes are the organisms 
stated contributing to acne pathogenesis. The bacterium resides in the lipid rich 
follicle and starts to multiply when the cornified plug blocks the outflow of sebum. 
PA triggers an adaptive immune response through its production of lipases and 
hydrolases and activation of toll-like receptors (TLR) on inflammatory cells. The 
ensuing inflammation is due to the rest products of the enzymatic pathways in the 
follicle, giving rise to proinflammatory and comedogenic substances. Chemotactic 
factors and activation of complement makes the wall of the follicle prone to rupture. 
When the inflammation engages the dermis a papule or pustule is formed(3, 4, 7). 
Acne and associated factors  
Interestingly there has been shown some correlation between diet and acne. Inuit’s 
diet rich in fish that was substituted for western foods comprising much saturated fat, 
had a rise in the incidence of acne. Indicated by Kwon, Yoon et al (2012) reduction in 
glycaemic load seemed to have a linear correlation to improvement of acne(15). A 
prospective cohort study conducted in Singapore of 94 school students with acne 
denoted on to what has been speculated by many researchers. Investigating sebum 
production and stress load, an increased stress load revealed to have a positive 
correlation with the severity of the acne, although it is not associated to sebum 
production(16).   
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Grading of acne vulgaris 
Acne severity is graded in several acne grading classifications globally. In Sweden 
most commonly used grading is from mild, moderate to severe acne. The different 
treatments are based on this classification.  
 Grade I/mild acne- Non-inflammatory comedonal acne with open and closed 
comedones with less than 10 inflammatory papulopustules located to the face. 
 
 Grade II/moderate acne- Comedones accompanied by between 10-40 
inflamed papulopustules located to the face. 
 
 Grade III/severe acne- Deep inflamed papulopustules less than 5 mm in 
diameter and more comedones than in grade II.  
 
 Grade IV/nodulocystic acne- Nodules greater than 5 mm in diameter with 
pseudo cysts, deep pustules and a large number of comedones. Scarring occur 
in this form(4, 17).  
Propionibacterium acnes resistance 
The establishment of which organisms that triggers acne has lead to targeted therapies 
towards PA. The bacterium is a gram-positive anaerobic organism residing in the hair 
follicle, harbouring high amount of sebum(18). When trapped in the clogged follicle 
it multiply and initiate inflammation through mechanisms that up regulates 
proinflammatory mediators. It is now known that the PA increased resistance since 
the last 30 years to commonly used antibiotics are leading to treatment failures of 
acne. Since it was first reported in the 1979, with time the same observations were 
made globally. Reviewed by Luk et al (2013) the prevalence of PA resistance in 
Europe is 5- 26.4 % for tetracycline and 45-91 % for erythromycin and clindamycin, 
not including Italy and Hungary which has a almost non-existent prevalence(19). 
Resistant strains can be passed to one another through person-to-person contact. The 
importance of the issue is in concern when selecting an appropriate treatment 
approach(20, 21). PA is the most resistant to erythromycin, thereafter tetracycline. In 
Sweden the use of minocycline is obsolete, although it has the least resistance of 
antibiotics used for acne therapy(18). Reasons for the apparent resistance are long 
duration of therapy, lack of compliance, over the counter products without clinician’s 
clearance, route of administration and the often prolonged or chronicity of the skin 
disease(22). The resistance has emerged through point mutation in the 16S rRNA in 
PA encoding for tetracycline and 23S rRNA encoding for erythromycin. Cross-
resistance between erythromycin and clindamycin is also due to point mutation in PA 
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genome(20). Studies have been made comparing different Minimum Inhibitory 
Concentrations so called MIC values to determine clinical significant sensitivity of 
PA to different antibiotics(23). According to Moon et al (2012) increasing MIC 
values has been undertaken the latest(20). As the most important antibiotic for 
treatment of acne in Sweden, tetracycline group is our focus in this systematic review. 
The PA strains investigated in a Korean prospective study involving 100 participants 
diagnosed with acne showed that the bacterium were susceptible to tetracycline. Even 
though the common use of tetracycline there is a low prevalence of resistant strains to 
this systemic antibiotic compared to other antibiotics(20). The question whether the 
PA resistance to antibiotics used for treating acne has a significant impact on the 
overall public health may be answered-- that it will in the long run. The reason for 
this is that other bacteria normally living on the skin also develop resistance for the 
same antibiotics used for acne. Coagulase-negative staphylococci (CNS) are one of 
those bacteria that might be a potential disease-causing organism in immune-
compromised persons. In turn resistance developed by CNS may transfer by plasmids 
to Staphylococcus Aureus(19). Ways to restrict the antibiotic resistance of PA 
conducted by the Global Alliance to Improve Outcomes in Acne group according to 
Thiboutot et al (2009) by(3): 
 
I. Always treat acne in a combination of antimicrobials and a topical 
retinoid. 
II. Do not precede antibiotic treatment for too long periods and if there is 
no improvement stop the therapy. 
III. Recommend simultaneous usage of products with benzoyl-peroxide 
(BPO) 
IV. Do not prescribe antibiotics in monotherapy (topical and oral)  
V. When changing antibiotic therapy it should be reasonable.  
VI. Oral and topical antibiotics are not to be used together. 
VII. Topical retinoid, preferably in combination with BPO could be used 
as maintenance therapy.  
VIII. Antibiotics should not be prescribed as maintenance therapy.  
Treatment of acne vulgaris 
When evaluating which therapy to prescribe, the severity and the extent of the lesions 
should be emphasized. Other factors to be determined are the duration of the acne and 
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previous treatments and the effects of these. If the patients skin is prone to scarring 
and heals with pigmentation is also weighed(4). The objectives for the therapy are to 
target the four pillars (increased sebum production, inflammation, hyperkeratinisation 
in the hair follicle and colonization of PA) of the pathogenesis to acne and to reduce 
the emergence of microcomedones and visible acne lesions(3). First-line treatment 
for grade I mild comedonal acne is firstly monotherapy with topical retinoids and if 
there is additionally inflammatory lesions, a topical antimicrobial could be added 
such as benzoyl peroxide (BPO). For grade II moderate inflammatory acne, therapy 
with topical retinoids and BPO are often used in fixed combination preparations. 
Those who do not have any effect by topical preparations alone, oral antibiotics are 
the first line treatment in moderate to severe papulopustular acne(4). The advantage 
of oral antibiotics is the anti-inflammatory- and bacteriostatic effect on PA(6). It’s 
favourable to use oral or topical antibiotics in combination therapy with retinoids or 
BPO, decreasing the risk of generating resistance(3). For females who also wish to 
have a contraceptive effect apart from the suppressive effect on acne, a hormone 
therapy would be an option. Hormone therapy is frequently prescribed together with a 
topical retinoid for maintenance therapy(24). For the most severe cases of acne, 
which is the nodulo-cystic form and acne conglobata, oral isotretinoin is the treatment 
that would be prescribed, only by specialist in dermatology in Sweden(12). Acne that 
do not improve with oral antibiotics and heals with scarring is likewise an indication 
for oral isotretinoin(24). Alternative treatment in this case is high-dose oral 
antibiotics together with topical retinoid and BPO(4).   
Topical therapy 
When starting with topical regimens the mainstay is to begin with non-antibiotic 
medication(6).  
Retinoids 
Retinoids are derivatives of vitamin A and is the group of topical therapy considered 
to be a cornerstone in acne treatment. Retinoids are functioning in a comedolytic 
fashion through regulation and counteraction of the keratinocyte proliferation and 
comedone formation(12, 24). Advantages of retinoids are the anti-inflammatory 
effect. Another effect is the increase in skin permeability, enhancing the effect of 
other topical medications such as antibiotics. Tretinoin and Adapalene are retinoids 
that are most commonly used for acne stated by an up to date study by Tirado-
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Sanchez et al (2013)(25). In the same study the efficacy rate for 90 days of treatment 
with tretinoin 0.05 % gel was 80 % and 70 % for Adapalene 0.3 % concentration. 
While the efficacy of Adapalene in the preparation 0.1 % concentration was the least 
it also had the least adverse reactions. Adverse reactions to topical retinoids are 
dryness of the skin, scaling, skin irritation, burning and postinflammatory 
hyperpigmentation. Tretinoin appeared to cause most adverse reactions(25). Tretinoin 
should not be used in combination with oral isotretinoin or BPO(12). The only form 
of a topical retinoid combined with BPO is the retinoid derivative adapalene(3). 
Antimicrobials 
Most commonly used is the bactericidal preparation benzoyl peroxide. The scaling of 
the superficial epidermis gives the keratolytic effect of this medication(26). Adverse 
reactions to BPO are skin irritation and it may bleach textiles and hair(12). Although 
topical antibiotics are not preferable there is a combination preparation named Duac, 
with BPO and clindamycin. This combination is anti-inflammatory and targets PA. 
With the so to say protection by BPO, antibiotic resistance is less likely to occur 
using this preparation(3). For maintenance therapy the medication Epiduo containing 
a fixed combination of BPO 2.5 % and adapalene 0.1 % is a good alternative to 
topical antibiotics. This therapy could be used for years having an effect on antibiotic 
sensitive and resistant strains of PA, the inflammation and hyperkeratinisation(6, 27, 
28). The importance of maintenance therapy is that microcomedones decrease while 
the active preparation is applied to the skin, discontinuation will often lead to 
recurrence of microcoemdones and acne(3).  
Antibiotics used in a topical preparation are clindamycin, erythromycin and 
tetracycline. Clindamycin is the only topical antibiotic in use in Sweden and 
treatment recommendations states it could be used for not longer than 3 months(6, 
11). Indicated earlier, topical antibiotics should not be used in monotherapy. 
Clinicians should prescribe topical antibiotics in a regimen together with BPO(11). 
Azelaic acid is also said to belong to the antimicrobial group since it inhibits the 
proliferation of PA and is comedolytic(29). Side effects of topical antibiotics are 
similar to retinoids producing skin irritation, dryness, scaling and burning. There is 
no evidence of emergence of resistance for therapy with BPO or azelaic acid 
according to Haider et al (2004)(11).  
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Oral therapy 
Oral Tetracycline 
If topical therapy have no effect in moderate to severe acne after 2 to 3 months of 
treatment, tetracycline group antibiotics is the first line treatment. These antibiotics 
are bacteriostatic and anti-inflammatory affecting chemotaxis(4, 6, 30). The severity 
of acne and the association between the numbers of PA is sparse. The reduction in 
number of PA by oral antibiotics do not correlate with the clinical efficacy stated by 
Burns et al. (2010)(4). In Sweden antibiotics from the cycline group indicated for 
prescription for acne therapy is only tetracycline; others in use globally are 
lymecycline, oxytetracycline and doxycycline. In other countries minocycline and 
erythromycin is also used(11, 31). Therapy duration for tetracycline is for 3 months at 
a dosage of 500 mg x 2 daily or tetralysal 300 mg x 2 with concomitant topical 
tretinoin or adapalene(12, 31). When cessation of antibiotic therapy, as maintenance 
therapy a topical retinoid may be considered(6). The spectra of effects and side 
effects of different tetracyclines are wide. Due to high efficacy of doxycycline and 
minocycline they are the antibiotics most predominantly prescribed in other countries 
than Sweden. When the patient cannot tolerate first line antibiotics and when in the 
second and third trimester of pregnancy or when breastfeeding, second line treatment 
is the macrolide erythromycin(12, 32). However erythromycin should not be used in 
the first trimester of pregnancy due to heart complications and it is also rather not 
used because of its high resistance of PA, but it is a choice if there has been treatment 
failure(30, 33). According to Leyden et al (2011) concerning the pharmacokinetics of 
tetracycline, the poor permeability results in 77-88 % absorption when taken 
orally(30). Tetracycline is not to be taken together with food, especially containing 
milk and other foods with iron, calcium and magnesium, though it leads to a 50 % 
reduction of the absorption. Even though the high solubility of tetracycline it is not 
really lipophilic and it cannot easily penetrate the lipid rich hair follicle. Minocycline 
and doxycycline have a good absorption and therefor is to a lesser extent affected by 
food. Because of its very high permeability and excellent uptake in lipid-rich sites, 
minocycline is very effective but may also give more adverse reactions. It crosses the 
blood brain barrier and may cause acute vestibular adverse events, intracranial 
hypertension and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS 
syndrome)(30, 34). However, stated by Burns et al (2010) the supposed higher 
efficacy of minocycline and doxycycline due to higher lipophilicity are not wholly 
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true as there is no good evidence for this(4). Side effects caused by tetracycline are 
gastrointestinal irritation with diarrhea, vomiting and dyspepsia. Vaginal candidiasis 
may occur in women and the influence when on the pill is not certain, giving 
recommendations to be extra cautious with contraceptives during therapy(4, 12). One 
particularly evident side effect in children is the potential yellowish discoloration and 
enamel hypoplasia of the developing teeth’s(4, 7). For this reason tetracycline should 
not be prescribed to children and pregnant women. Rare adverse effects are benign 
intracranial hypertension and photosensitivity(7). Considering a good treatment 
outcome, the number of PA is reduced(4).    
Oral Isotretinoin 
Since it was introduced on the market in the early 1980’s, oral isotretinoin is the 
number one treatment with the potential to completely cure acne. Isotretinoin is a 
synthetic derivative of vitamin A, targeting all four causative factors in the 
pathogenesis of acne(4, 12, 27). It is not perfectly defined how isotretinoin exerts its 
effects, however the effect on sebaceous glands is remarkable having the potential to 
reduce sebum excretion by 90 % in 6 weeks in administered dosage of 0.5-1.0 
mg/kg/day(3, 4). With the decrease in sebum production the decline in colonizing PA 
is evident thereby indirectly having an antimicrobial and anti-inflammatory action. 
The prescription of the medication is reserved for specialist in dermatology for severe 
acne that is reluctant to antibiotics(4, 12). Due to adverse effect such as teratogenicity, 
female patients must persist on oral contraceptives before, during and 2 months after 
the therapy(24, 31). Mandatory pregnancy testing before and every 4-week under 
therapy is the routine. Even patients with moderate acne that have no effect of oral 
antibiotics could be considered for treatment with oral isotretinoin(4). Indications for 
oral isotretinoin are patients with moderate to severe acne with no improvement with 
oral antibiotics and topical therapy after 3 months, acne with post inflammatory 
hyperpigmentation or scarring, relapsing acne and those with systemic reaction(31). 
Recommended dosage to start with is 0.5 mg/kg/day, regulating the dosage following 
the result and tolerability of the patient(27). The absorption is doubled when taken 
together with food and is therefor recommended. Therapy is usually until a total 
dosage of 120 mg/kg of body weight is achieved(4, 12, 31). In the previously stated 
dosage about 85 % of patients gained remission after 16 weeks of therapy(4). 
Commonly experienced adverse effects (AE) are chelitis, conjunctivitis, dermatitis, 
facial erythema, dryness of lips and skin and mucositis(24). Not as common but 
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important to mention is AE giving headaches, benign intracranial hypertension, mood 
changes and depression(11). In a retrospective cohort study conducted in Sweden by 
Sundström et al (2010) they found data suggesting an increased risk of suicide 
attempts 6 months after therapy with oral isotretinoin. Notably the evident risk was 
already present before starting on therapy(35). If adverse reaction appears such as 
depression, cessation of the therapy is crucial. Typically liver enzymes and 
triglycerides may rise during isotretinoin therapy. Therefor these values should be 
monitored during therapy(4). Important actualities are that tetracyclines should not be 
prescribed to patients on oral isotretinoin, though both have the potential of causing 
benign intracranial hypertension(24, 31).  
Objectives 
In this systematic review we would like to assess the effect and side effects in 
patients diagnosed with mild, moderate to severe acne in ages 11 to 42 who received 
different treatment in acne. Treatment with tetracycline alone or in combination 
therapy compared to control groups allocated to other regimen with antibiotics, 
topical regimen, oral isotretionin or placebo. Primary objectives are to evaluate the 
efficacy of treatment with tetracycline comparative to other therapies. Furthermore to 
evaluate side effects in commonly used therapies in relationship to oral tetracycline. 
Secondary objectives are to determine outcomes in therapy related to PA resistance. 
Moreover reviewing trends in prescription of different treatment for acne relating to 
PA emerging resistance is of interest, reserved for the discussion part. Preferably 
randomized control studies (RCT) are selected because they provide the highest 
evidence.  
Methods 
A handmade protocol for the search was conducted together with the project 
supervisor and project colleague. Inclusion criteria and outcomes to be measured 
were specified prior to the search. Information was collected from textbooks in 
dermatology and a systematic database search. Certain information was hand 
searched on the web, providing the quantitative information needed to the review as a 
whole. Inclusion criteria are studies that were assessing acne vulgaris, tetracycline 
and treatment in acne. Those criteria were measured in a wide array of interventions 
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in studies we sought. Studies selected were those with our predetermined Participants, 
Intervention, Comparator group, Outcome and Study design (PICOS) with the 
outcomes stated in the objectives. Keywords such as treatment, therapy, regimen, 
effect, side effect, efficacy and adverse effect in context with acne vulgaris and 
tetracycline were to be evaluated, meeting inclusion criteria in the title or in the 
searched abstracts. Outcomes to be examined such as effect and efficacy of 
tetracycline in treatment in acne vulgaris was decided in advance. Other outcomes 
were side effects of tetracycline in treatment of acne patients. Along the process we 
discovered that numerous studies were assessing PA resistance related to different 
acne regimen. This was also selected as a secondary objective bringing an important 
research question into light of this review.  
Eligibility criteria 
Study characteristics composed participants that had been diagnosed with acne 
vulgaris. Graded form mild-moderate to severe acne, including as many studies as 
possible. Although acne is most prevalent in adolescence, included participants had to 
be in the age range between 11 to 42 years to widen the selection. The intervention 
was treatment with oral tetracycline with no specified dosage or timespan and 
assessment of the efficacy and side effects of the therapy in comparison to other 
regimens. Because both first and second-generation tetracyclines are used globally 
for acne, studies assessing comparative intervention with those antibiotics in relation 
to tetracycline are included. Microbiological examination of resistant PA in clinical 
trials is also of interest, possibly evaluating indirectly the effectiveness of tetracycline 
and other commonly used acne therapies.  
 Primary outcome: to evaluate the effect or the efficacy and side 
effects/adverse effects of therapy with oral tetracycline in acne vulgaris.  
 Secondary outcome: PA resistance to tetracycline and what impact it may 
have on acne therapy outcome.  
Studies selected were limited to those in the English language with a 10-year span 
ranging from 2002-2012. Study designs preferred are those with a clinical focus, 
randomized with a control group receiving intervention or placebo. Cohort studies 
with a follow up for at least one year are to be included. No imposition was made 
about payment. Reports only with full-text and all data published were selected. 
Excluded studies were in-vitro studies, single case reports, review articles and studies 
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not concurrent with any of the measures in the specified PICO. Additionally 
observational studies and studies with less than 30 participants was excluded. Criteria 
for inclusion and exclusion are displayed in table 1. 
Table 1 – Inclusion and exclusionlist table 
Inclusion and Eligibility Criteria Exclusion Criteria 
English language In-vitro studies 
Published studies, year span 2002-2012 Case- reports 
Full-texts Review articles 
Studies with control group, not only 
placebo 
Studies not concurrent with PICO 
Ages 11-42 years Expert opinion based on theory studies 
Mild to severe acne vulgaris Observational studies 
Tetracycline compared to other acne 
therapies 
Studies with less than 30 participants 
  
Inclusion and eligibility criteria for the study featured in the left column and exclusion criteria in 
the right column.   
Information sources 
Databases electronically searched were PubMed, Scopus and Cochrane library. The 
primary search was made in September 2012, although it had to be modified because 
the inclusion criteria in the primary protocol were too wide generating over 147 
studies with about 65 studies assessed for eligibility. Modifications made were 
limiting the studies selected to a 10-year span instead of a 20-year span that were 
selected at first. This limiting factor filtered out studies that did not meet the inclusion 
criteria. Moreover suggestions in the search menu bar for example selecting search 
area; “medicine” and “pharmacology, toxicology and pharmaceutics” were chosen. 
The latest updated search was run the 16 of may 2013 searching all three databases 
and ended the 22 of may 2013. In spite of 2012 have already past, the decision to still 
follow a 10-year span starting and ending according to the first set inclusion criteria 
was agreed upon. Additional studies were hand searched from the included studies 
reference list. However, this hand search did not contribute to any qualitative 
additional studies that could be included. Reference lists were checked for all studies 
selected to full-text assessment for eligibility, providing up to date information about 
different aspects in acne and acne treatment brought up in the final review.  
Search 
Search terms conducted for PubMed, Scopus and Cochrane library was “Acne 
vulgaris” and “Tetracycline”. For all three databases, limitations to the “English 
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language”, year range, from 2002 to 2012 were selected. For PubMed the search term 
was sought in “title and abstract” and for Scopus database in “abstract” thought there 
was no comparable choice to be selected. In Cochrane library search terms were 
sought in “trial, Cochrane review”. Additional selections in Scopus had to be made 
because of the large sample size, limiting to “medicine” and “pharmacology, 
toxicology and pharmaceutics” matching our focus. Because of many hits of different 
kinds of document types, limiting to “review” and “article” was necessary in Scopus.  
Study selection 
Selection of studies was made according to the predetermined protocol with inclusion 
and exclusion criteria. One person conducted the search process. Inclusion criteria 
were modified along the way when doubts occurred and when studies appeared that 
was not discussed for eligibility in advance. Such complications were solved together 
with the project colleague and the supervisor. For the assortment of studies at the end 
of the search the selection was carried out together with the supervisor. A flow 
diagram was used to overview the search designed by “Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses” (PRISMA)(35). 
Data extraction 
Methods for data extraction were made by presenting studies in a manner similar to a 
template designed by the Cochrane Collaboration Qualitative Methods Group, 
2011(25). One person extracted all data in a systematic manner to reduce risk of bias. 
For each study PICOS were brought up and reported in the results. 
Data items 
Outcome measures were presented in tables in the appendix for each outcome 
identified in the studies. The template was conducted by Health Technology 
Assessment-Centrum(31). In the table headlines is author/year, country, study design, 
number of patients, withdrawals/drop-outs, result- intervention/control, comments 
and risk of bias. Information about the specific study designs was furthermore 
presented in text form in relation to PICOS reviewed by one person. The report 
structure is based on the PRISMA-statement design(35). 
Risk of bias in individual studies 
When assessing risk of bias for each study a modified checklist by Swedish Council 
on Health Technology Assessment(28) was used screened by one person. Bias to be 
examined is external validity, internal validity, study limitations and precision. 
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Additionally an overview of the risk of bias in the individual studies were tabulated 
according to Cochrane Collaboration(25).  
Summary measures 
In summary measures, efficacy of treatment with tetracycline was presented in what 
form studies presented their data including for example relative risk with confidence 
intervals or odds ratios. If it proved that studies included in the qualitative analysis 
had a wide variety of methods for conducting studies and did not have a coherent 
effect measure, the results were not added to a meta-analysis with the enlarged risk of 
producing bias. Meta-analysis was conducted if it was appropriate.  
Risk of bias across studies 
For evaluating the risk of bias across studies and quality such as allocation 
concealment, blinding, selective reporting the GRADE work sheet was assessed for 
this(26).  
Ethics 
Establishment of an ethical dilemma did not prove to be necessary for this systematic 
review though ethical approval and appraisal have already been weighed in the 
studies within this exploration. Although the studies included did not present any 
ethical issue it is essential for further researches to take notice that these kinds of 
studies may be redone in the same fashion with no reservations.  
Results 
Study selection 
The complete number of records identified through the primary database search in 
PubMed, Scopus and Cochrane Library generated 95 studies. To be more precisely 40 
studies were obtained from PubMed, 44 from Scopus and 11 from Cochrane library. 
The search conducted in each database was screened and compared to each other and 
duplicates were removed. A number of 36 studies were excluded because of 
duplicates. A total of 59 studies were left for the assessment of title and abstract for 
inclusion in coherence with the protocol. Several articles were eliminated at this point, 
not meeting the criteria for inclusion. An exclusion list/table was piloted with 
comments provided alongside reason for exclusion, see appendix. After 48 articles 
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were excluded there were 11 studies left in full-text for assessment of eligibility. Of 
these studies, 9 were extracted from PubMed and 2 from Scopus. However, after 
discussion with my supervisor Jan Faergemann about the eligibility criteria with 
focus on the primary outcome, it was evident that an extra exclusion criteria hade to 
be set up. Not all of these studies were of interest when assed in full-text because 4 of 
them were in-vitro studies and 1 were measuring the wrong outcome. Then another 5 
articles were excluded. Temporary 6 studies were selected for the final study, out of 
these, 3 studies had to be excluded because of low evidence entailing to observational 
studies. Out of the 3 remaining RCT studies that maid it to the final qualitative study, 
all was extracted from PubMed database. The complete search is displayed in a flow 
diagram in the appendix. 
Study characteristics 
For the remaining 3 studies all of them were randomized controlled trials. They were 
all accessed in full-text and in the English language meeting eligibility criteria. The 
studies were carried out in Sweden, Iran and the United States. The duration of 
intervention was 6 months with a 2-month follow-up in “Clinical and Microbiological 
Comparisons of isotretinoin vs. tetracycline in Acne Vulgaris” by Oprica et al 
(2007)(36), 3 months in “azitromycin versus tetracycline in the treatment of acne 
vulgaris” by Rafiei et al (2006)(29) and 18 weeks in “Comparison of five 
antimicrobial regimens for treatment of mild to moderate inflammatory facial acne 
vulgaris in the community: randomised controlled trial” by Ozolins et al (2004)(34). 
A total of 991 participants were enrolled to the included studies. Similarities in the 
inclusion and exclusion criteria were found for the studies. Participants were in the 
age range 11- 42 and were diagnosed with mild- moderate or severe acne vulgaris. 
Exclusion criteria for enrolment were in brief summary, participants that recently had 
been on systemic treatment for acne, with systemic disease or other dermatological 
disease, with a hormonal disorder or with a drug induced acne. Pregnant women, 
participants planning to get pregnant or women who were breastfeeding were also 
excluded. Those who were taking medication that could interfere with the outcome 
and if any experienced hypersensitivity reaction or allergic reaction to the drugs 
tested were excluded. Those participating in other clinical trials were excluded in two 
studies. The intervention in all three studies was oral tetracycline, alone or together 
with a topical regimen compared to other common acne therapies. In two studies skin 
samples were taken for bacterial culture, most often form the face. They were 
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incubated on blood agar plates to determine the density and frequency of PA 
resistance. Studies were performed to determine the MIC of tetracycline and other 
antibiotics or regimen for acne treatment to PA.  
In one study comparison was made between tetracycline and oral isotretinoin. In 
another study oral tetracycline was compared to azithromycin, a macrolide antibiotic 
similar to erythromycin. One study compared five regimens in acne that all displayed 
antimicrobial properties. Two studies combined topical retinoids in their intervention 
in some way. Outcome measures that are shared in the studies were the efficacy of 
the treatment, adverse effects connected to different regimens and evaluation of PA 
resistance to tetracycline compared to other acne treatment. One study assessed the 
quality of life in relation to the influence of the skin disease. Tables for the different 
shared outcomes are provided in the appendix.  
For simplification, the studies will hereafter be named Study I to III. Study I is Oprica 
et al (2007), study II is Rafiei et al (2006) and study III is Ozolins et al (2004). 
STUDY I 
The aim of the study conducted by Oprica et al (2007)(36) was to determine clinical 
efficacy and microbiological efficacy on PA in treatment with oral tetracycline plus 
topical adapalene compared to oral isotretinoin. 
Participants were enrolled from patients at Karolinska University Hospital Huddinge, 
Stockholm at the Dermatology department. Diagnostic criteria were moderate to 
severe inflammatory acne vulgaris graded in line with “Leeds technique”. In this 
meaning, moderate acne was a manifestation with papulo-pustular and nodular acne 
lesions. Severe acne diagnosis was given to those with the nodular form adjoining the 
conglobated form. The age group assessed were 15-35 years and 52 participants were 
enrolled with 26 participants in each group. Reasons for exclusion were participants 
who had used acne therapy in the previous 8 weeks or who had taken oral isotretinoin 
within 12 months. Pregnant women, those with intention of getting pregnant and 
breastfeeding women were excluded. Participants that were under medications that 
could interfere with tetracycline for example; antacids, iron supplements, 
anticoagulants and retinoids, were excluded. Those with other skin diseases; patients 
who were participating in other clinical trials or who had experienced hypersensitive 
reaction to the drugs to be allocated in the study were also excluded. Patients were 
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randomly allocated to either oral tetracycline 500mg twice a day + topical adapalene 
0.1 % (TET/ADA group) once a day or oral isotretinoin(ISO group) in two divided 
doses of 1mg/kg/day. Samples for skin bacterial cultures were taken to assess clinical 
outcome relative the density and antimicrobial susceptibility of PA. The samples 
were taken at baseline and at 2, 4 and 6 months of treatment and at the 2 months of 
follow up. One person, not participating in the study with a code generated by a 
computer, knew the randomization process. Both groups were treated for 6 months 
with a follow-up at 2, 4 and 6 months and thereafter 2 months after termination of 
therapy. Only the TET/ADA group received maintenance therapy with topical 
adapalene after 6 months of oral therapy. The ISO group were informed not to take 
other medications containing vitamin A, tetracycline and aspirin due to potential 
adverse effects. The women in the ISO group received oral contraceptives before, 
during and after the treatment. The TET/ADA group was informed about possible 
adverse effects on foetuses, not to become pregnant during therapy. Antiseptic 
cosmetics were not allowed due to the risk of interfering with the bacterial cultures 
performed. Information about limitation of sun exposure was given. Methods to 
examine the clinical efficacy were determined in advance. Two dermatologists 
assessed this independently. For baseline and all follow up visits, lesions were 
counted and graded according to Leeds technique. Assessment of the face, chest and 
the back was done based on the type of lesion: non-inflammatory, superficial and 
deep inflammatory. Another assessment of the effect of treatment was the patient’s 
experience of the treatment and the impact of skin disease in relationship to quality of 
life. Participants filled out a self-administered questionnaire before and after 
treatment. Microbial samples were taken from the forehead, left and right cheek, back 
and chest. The samples were incubated on blood agar with antibiotics at breakpoint 
values.  MIC values were measured for each antibiotic tested and resistance to any 
antibiotics was stated if the bacteria were growing in spite of breakpoint values or 
over the breakpoint value. Breakpoint values were concurrent with the European 
Committee on Antimicrobial Susceptibility Testing recommendations. Tested 
antibiotics were tetracycline, clindamycin, erythromycin and linezolid.  At the follow 
up visits participants were asked about experience of any side effects. The ISO group 
was monitored with blood count, liver enzymes, cholesterol and lipids. A complete 
blood count was taken of the TET group.  Statistical analyses used were specified in 
advance in an intention-to-treat population.  
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 STUDY II 
The aim of the study conducted by Rafiei et al (2006)(29) was to compare the 
efficacy and safety of treatment with azithromycin versus oral tetracycline in acne 
vulgaris.  
Participants were enrolled from the outpatient clinic of Emam Khomeini University 
Hospital, Ahwaz, Iran. A number of 290 patients met their inclusion criteria. Those 
with moderate to severe papulopustular acne vulgaris were selected. Additional 
inclusion criteria were acne that appeared for the first time or relapsed. Excluded 
were participants with systemic disease, hormonal disorders and those with drug-
induced acne. Pregnant and breastfeeding mothers were not included. Patients that 
hade received systemic acne therapy during the past 3 months were excluded. If 
previous drug reactions had appeared for the medications to be allocated they were 
excluded. Two groups of participants were randomly allocated to either a therapy 
with oral azithromycin or oral tetracycline for 3 months, with a number of 148 
participants in the group receiving azithromycin and 142 in the group allocated to 
tetracycline. The dosage for azithromycin was in pulse dosage, starting the therapy 
with 500mg/day for 3 consecutive days in a week for a month. Subsequently a 
decreased azithromycin dose of 250mg/day every other day was given for the last 2 
months. The other group received 1g/day of oral tetracycline for one month, 
thereafter 500mg/day for 2months. For the last 2 months of therapy, topical tretinoin 
0.05 % was added to the regimen in both groups.  Classification of acne severity was 
based on number of lesions and the location. The study was randomized in that sense 
that every other patient was allocated to one specific treatment by the clinician. A 
blinded investigator measuring the outcome held the follow-up visits. The follow-up 
was conducted after 1 and 2 months. In the last visit patients were asked about 
adverse effects and compliance. Further exclusion of participants was due to lost of 
follow up, a total of 54 patients left the study for this reason. Statistical analysis was 
chosen in advance and the study was done in a per-protocol analysis.  
STUDY III 
The aim of this study conducted by Ozolins et al (2004)(34) was to examine the 
efficacy, cost-effectiveness and treatment outcome in relation to PA resistance for 
five antimicrobial regimens in mild to moderate acne vulgaris.  
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This was a randomized study with 649 participants with the intention-to-treat. A 
number of participants were enrolled from the National Health Service network and 
some additional from colleges. Criteria for inclusion was mild to moderate acne 
vulgaris. This estimate was based on identification of 15 non- inflammatory and 
inflammatory lesions located in the face. Exclusion criteria were: acne secondary to 
other disease or medication, nodular, truncal and comedonal acne was also rejected. 
Additionally pregnant women or women with intent to get pregnant and breastfeeding 
mothers were excluded. Acne with late onset (>26 years) was also excluded. Those 
with previous therapy with oral isotretinoin or other on-going acne therapy treated by 
a dermatologist had to be excluded, not to interfere with the result. Participants 
participating in other clinical trial and any with known hypersensitivity to the 
allocated regimens were excluded. Participants were not allowed to use any acne 
regimens for 4 weeks before the start of the study. The 5 different interventions that 
were allocated is visualised in the table 2. 
Table 2- Regimen in study III Ozolins et al 
 Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 
Oral 
500mg 
oxytetracycline 
1x2 
100mg 
minocycline 
1x1 
Placebo 1x1 Placebo 1x1 Placebo 1x1 
Topical Placebo cream twice a day 
Placebo 
cream twice a 
day 
5% benzoyl 
peroxide 
twice a day 
5 % benzoyl 
peroxide + 
3% 
erythromycin 
twice daily 
2% erythromycin 
in the morning, 5% 
benzoyl peroxide 
in the evening 
Different regimens that were allocated in study III. Regimen 1-5, oral and topical treatments. Oral 
placebo in regimen 3-5 and topical placebo in regimen 1-2.  
A computer generated code allocated participants to their specific regimen. The 
coordinator of the trial and the pharmacy staff delivering the regimens at baseline, 
after 6 weeks and at the 12 week of follow up knew this code. The regimens were 
delivered in opaque boxes. Reason for placebo treatments was to standardize the trial 
and minimize bias. Participants were instructed not to discuss their treatment 
specifics with their assessors who were blinded. Outcomes assessed were self 
reported moderate improvement on a 6- point likert scale at the follow up visits and 
number of lesions.  Skin swabs were taken at the follow-ups and evaluated for PA 
resistance to different antibiotics. Adverse effects were monitored at each follow-up 
visit.  
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Risk of bias in individual studies and across studies 
The risk of bias in individual studies regarding the directness concerning the study 
population and its external validity was overall good. Only one study, Oprica et al 
(2007) did not display data with the study population and participants excluded 
before randomization. The internal validation measuring the process of randomization 
was done in a fashion minimizing the risk of manipulation using a computer 
generated code for allocation in Oprica et al (2007) and Ozolins et al (2004). All 
participants that were selected for the randomization received the intervention. 
Though all three studies were conducted in a parallel-group design, meaning that all 
groups received an intervention they were all similar and comparable. To reduce the 
risk of confounders such as age, gender and different acne severity, those measures 
were taken in to consideration in the final analysis by stratification. The most 
concerning factor was the lack of masking participants and clinician in all studies. 
However, investigators measuring the outcome were blinded in Ozolins et al (2004) 
and Rafiei et al (2006). The dropout was acceptable through out studies with a 
dropout of 13 participants in study I, 54 in study II and a drop out rate of 23% in 
study III. It was measured upon in advance in Ozolins et al (2004) to detect a 
minimum relative effect of 30 % of one regimen compared to the other 4 regimens 
with an 80 % power. Adherence was taking in to consideration in all studies, often 
the participants were asked about it or the clinicians collected unused packages 
containing the intervention drug.  Information on how to provide effect measures in 
the final synthesis was determined in advance for all studies. The reporting was less 
satisfactory in Rafiei et al (2006) compared to the other two studies. Likewise the 
precision relating to the presentation of the results, methods of measuring effect and 
power-analysis was not as detailed as desired in this study compared to the other 2. 
Ozolins et al (2004) was the only study bringing up declaration of interest and 
conflict of interest statement. Study characteristics are presented in table 3. When 
assessing the overall evidence, a worksheet evaluating quality of evidence was used 
designed by the GRADE workgroup(26). For all outcome measures the quality was 
assessed in summary. Outcome for evaluating the side effects of tetracycline 
compared to other regimen, the quality of evidence was moderate. Outcomes for 
efficacy of oral tetracycline and the evaluation of PA resistance to tetracyclines, the 
average quality of evidence was low. See GRADE table in the appendix. 
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Table 3- Study characteristics table 
Trials Concealment of Randomisation 
RCT stopped 
Early 
Patients 
Blinded 
Health Care 
Providers 
Blinded 
Data 
Collectors 
Blinded 
Outcome 
Assessors 
Blinded 
Oprica et al., 
(2007) Yes No No No No No 
Rafiei et al., 
(2006) No No No No Yes Yes 
Ozolins et al., 
(2004) Yes No No No Yes Yes 
Study characteristics are presented for all three studies. Oprica et al and Ozolins et al both provided 
a satisfactory concealment of randomisation. In none of the studies patients and health care 
providers were blinded. Only Rafiei et al and Ozolins et al had data collectors and outcome 
assessors that were blinded about the treatment.  
Syntheses of Results  
Tables for the three outcome measures are provided in the appendix.  
Outcome 1- Efficacy evaluation 
In Study I there was a reduction of superficial inflammatory, deep inflammatory and 
non-inflammatory lesions (p<0.001) for both groups after 6 months. A significant 
difference in reduction in non–inflammatory lesions was seen between the tetracycline 
plus adapalene group compared to the oral isotretinoin group after 2 months. Likewise 
in superficial inflammatory lesions a significant reduction was seen after 4 months. 
Oral isotretinoin had the greatest reduction of lesions, even in the follow up period. 
The TET/ADA group had an increase of all lesions in the follow up period. The 
reduction was quite similar in both groups for deep inflammatory lesion. At the end of 
the 6 months of therapy, 16.6 % in the oral isotretinoin group had no inflammatory 
lesions compared to 4 % in the TET/ADA group (p>0.05). At the end of the follow up 
period no one in the TET/ADA -group had any inflammatory lesions compared to the 
oral isotretinoin group where 20.8 % had no inflammatory lesions. When the treatment 
was discontinued, only the ISO group showed a persistent decrease in acne severity 
(p=0.052). The overall difference during the 6 months of therapy was not significant 
between the groups, however after the follow up, isotretinoin had an advantage 
(p=0.009).  
In Study II, the group receiving tetracycline, 48.3 % had a moderate improvement 
compared to 40.7 % in the azithromycin group. While measuring good to excellent 
improvement, azithromycin had a 44 % improvement and was superior to tetracycline 
by 31.4 % after 3 months of therapy for both measures. Partial or complete resolution 
of acne was seen in 84.7 % in the azithromycin group compared to 79.7 % in the 
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tetracycline group. There was no significant difference when measuring clinical 
response rate between both groups (p>0.05).  
The efficacy in Study III was compared between regimen 1 and 4 in this systematic 
review because this comparison was the most interesting relating an oral therapy to a 
fixed topical drug combination. The study showed similar efficacy between all 
regimens. The improvement of the acne severity according to participants at 18 weeks 
in odds ratios (95 % CI) for regimen 4 versus regimen 1 was 1.64 (0.98-2.74). After 12 
weeks of therapy regimen 4 had a 61 % improvement according to assessors compared 
to regimen 1 which had a 47 % improvement. Regimen 4 was significantly better than 
regimen 1 when assessing reduction in acne severity after 18 weeks with a difference 
of 0.18 (0.06-0.29) when adjusted for confounders.  
Outcome 2- Side effects evaluation 
In Study I, side effects were monitored through out the treatment. In the tetracycline 
plus topical adapalene group, 10 % experienced side effects such as abdominal pain 
and transitory nausea. 15 % reported dry skin, redness and itching of the skin once 
during the treatment. The other group allocated to oral isotretionin had a higher 
percentage of adverse effects after 2 months of therapy, relating to dryness of the skin 
91.4 %, inflammation of the lips 95.8 %, dry eyes 75 % and nose bleed 54 %. Some 
of the side effects improved after 6 months and after stopping treatment 83 % hade no 
adverse effects. One patient experienced an acne flare and had to discontinue the 
treatment. Dryness of the skin made 2 participants discontinue the treatment. Three 
participants complained of tiredness and fatigue. One patient had a transitory increase 
in liver enzymes. Although within normal range, many patients in this group had an 
increase in triglycerides.  
Similar to Study I, 11 % in the tetracycline group reported gastrointestinal side effects 
in Study II. 6.8 % experienced epigastric pain, 4.2 % complained of diarrhea and 2.5 % 
experienced vulvovaginal pruritus. In comparison to the tetracycline group, 10.9 % 
experienced gastrointestinal side effects in the azithromycin group. More specifically 
5% complained of heartburn and epigastric pain and 5.9% complained of diarrhea. 
When comparing for example regimen 1: oxytetracycline plus topical placebo to 
regimen 4: Oral placebo plus topical erythromycin in combination with benzoyl 
peroxide in Study III, regimen 1 gave more side effects compared to regimen 4. In 
regimen 1, 22 participants complained of gastrointestinal upset, 11 of central nervous 
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system (CNS) symptoms relating to headache and 5 experienced skin irritations out of 
131 participants after 6 weeks. In relation to this numbers, regimen 4 consisting of 127 
participants, 8 participants experienced gastrointestinal upset, 4 had CNS symptoms 
and 11 had skin irritation. Both groups had similar mean patient-assessed –irritation 
score.  
Outcome 3- P.acnes resistance evaluation 
In Study I both groups gave an overall reduction of colonization with PA. However in 
none of the groups there was a significant reduction in resistant PA. At baseline the 
TET/ADA group had more resistant strains of PA than the ISO group, but after 
adjusting for confounders there was no difference. After the 2 months of follow up 
there was a higher probability for the TET/ADA group to have a higher quantity of 
resistant PA to clindamycin and tetracycline compared to the ISO group with odd 
ratios of 0.06, 95 % CI (0.013-0.37), p<0.01 for TET/ADA and 0.05, 95 % CI (0.006-
0.49), p<0.001for the ISO group. After 6 months of therapy, the TET/ADA group 
gained resistant strains of PA whereas in the ISO group it remained constant or was 
lost. There was no statistically significant association between the occurrence of 
tetracycline resistant strains of PA and clinical response in the TET/ADA group or the 
ISO group.  
In study III the impact of PA resistance was measured as the effect of colonization with 
tetracycline-resistant PA on treatment outcome. Of patients that were colonized with 
resistant strains, 47 % reported moderately improvement at 18 weeks compared to 
56 % in patientes that had no resistant strains to tetracycline. In the same measurement 
for regimen 4 there was a reported improvement of 65 % for participants with 
tetracycline-resistant strains compared to 67 % in those that had no resistant strains. 
The reduction of mean skin lesion count after 18 weeks was significantly less effective 
for regimen 1 versus regimen 4 in those with resistant strains 23.1 (11.8-34.5). 48 % of 
participants in regimen 4 were colonized with erythromycin-resistant PA at baseline. 
After 18 weeks of treatment there was a reduction of 9 % in the participants. The 
number of erythromycin-resistant PA had no effect on participants rating themselves as 
moderately improved compared to regimen 1 with tetracycline resistant strains of PA. 
Topical erythromycin gave the largest reduction (16 %) in population of all PA strains 
after 18 weeks.  
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 Discussion 
Summary of evidence 
In spite of the relatively diverse quality of the three RCT studies assessed in this 
review, oral tetracycline showed to have no superior efficacy in relation to oral 
isotretinoin, azithromycin and the combination therapy benzoyl peroxide plus topical 
erythromycin. Our conclusion is that treatment with topical antimicrobials have 
similar or equal efficacy as oral tetracyclines. It seems that the key component to 
establish a good response on acne lesions is by the anti-inflammatory effect. Topical 
antimicrobials such as erythromycin act in an anti-inflammatory fashion, as does 
BPO indirectly by reducing the number of PA’s. The main action of oral antibiotics is 
by the anti-inflammatory effect and it could explain why PA’s resistance to 
tetracyclines did have no influence on treatment outcome in Oprica et al (2007).    
There was no robust evidence to certainly appraise the efficacy of treatment with oral 
tetracycline throughout studies. Factors that were not always comparable were 
different inclusion criteria for enrolment, grading of acne severity and the study 
designs conducted. In Study I and II, tetracycline was combined with topical therapy 
which makes it difficult to distinguish what effects was produced by the respective 
drugs alone. It is most likely that synergistic effects affected the outcome. However 
tetracycline is a tolerable and effective alternative treatment to oral isotretinoin in 
acne vulgaris, according to Oprica et al (2007)(36). Also suggesting that topical 
therapy antimicrobials could be a good alternative treatment according to the results 
of this review.  
Evidence grade was generally moderate for evaluation of side effects, while they 
were assessed in the same manner and was similar in all 3 studies. The most common 
side effects complained about in those who received oral tetracycline were 
gastrointestinal upset with epigastric pain and diarrhea, which is according to the 
other literature(24, 37). Adverse effects such as photosensibility were not assessed in 
any of the studies, maybe because of the lower prevalence or because information 
about limiting sun exposure was informed in advance. Women in the tetracycline 
group complained about vulvovaginal pruritus, a side effect not apparent in the other 
control groups receiving other regimens. Side effects with dry skin, redness and 
irritation of the skin was produced by the topical therapy when this side effects was 
experienced in the tetracycline plus topical therapy group. Dryness of the skin is an 
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attribute of oral isotretinoin therapy, therefor making it problematic to blind the 
clinicians assessing the outcome for this group during the study, though this adverse 
effect is evident. Side effects generated by tetracyclines were interpreted to be more 
tolerable in comparison to oral isotretionin. Adverse effects produced by topical 
therapy were not assed in comparison to oral tetracyclines. This comparison is 
difficult to make because of different routes of administration and ways of exerting 
its effects.  
When assessing dropout rates due to adverse effects, it was higher in the group 
receiving only topical therapy compared to the groups receiving systemic therapy in 
Study III. This association was also made in Nast A Fau et al (2012) where no 
conclusion could be made with sufficient evidence to determine whether topical or 
systemic therapy is superior to one another in acne(38).  
To generate a more definite comparison and evaluation of the efficacy of oral 
tetracycline, a study conducted comparing oral tetracycline alone versus another 
therapy in monotherapy is of interest. This could for example comprise topical 
adapalene, oral isotretionin or topical erythromycin. However with the increase of 
resistant PA, monotherapy with antibiotics is not preferred(38). Acceptable evidence 
particularly for Study I, which was conducted in Sweden, stated that there was no 
impact on treatment outcome in relation to the number of resistant PA colonizing the 
skin. However in Study III, the presence of tetracycline resistant PA’s had a 
significantly impact on treatment outcome when treated with oxytetracycline and 
minocycline. The trend is towards favouring the conclusion made in study III. Several 
studies have likewise suggested that PA resistance have a negative influence on 
treatment outcome(23, 39, 40). Important to take notice is that the difference between 
these two studies previously mentioned was that the latter did not use topical 
retinoids during and as maintenance therapy to the oral therapy. It is now well known 
that combination therapy with a topical retinoid is much more effective than oral 
therapy alone(38).  
Although tetracyclines are not as effective as the previously mentioned treatments in 
acne, it gives few side effects, is easier to prescribe, needs no monitoring of blood 
chemistry and reduces inflammatory lesions in a satisfactory way. As previously 
suggested in the background of this review by Chiou et al (2010) was that oral 
tetracyclines did not have a superior efficacy compared to placebo therapy(10). None 
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of the 3 studies assessed compared oral tetracycline in monotherapy versus strict 
placebo therapy. Therefor it is difficult to draw any conclusions about the efficacy of 
tetracycline alone.  
The trend in prescription of acne therapy has changed over the last years. According 
to Thevarajah et al (2005) there were a significant decline in the 1990-2002 in 
prescription of antimicrobial therapies, while there was an significant raise in the 
usage of non-antimicrobial regimens such as topical and oral retinoids(41). This 
observation was suggested to have a relationship to the awareness of the increase in 
PA resistance to antibiotics(41). In another study conducted by Kinney et al (2010) 
assessing the same topic, there was a significant increase in prescription of 
tetracyclines from 1997-2006 and a drop in prescription of erythromycin and oral 
isotretinoin(42).  
It is evident that oral isotretinoin is more effective in treatment outcome in 
comparison to oral tetracycline. The effectiveness of oral isotretionin comes from its 
fast onset of action and the wide target of exerting its effects and the prolonged 
remission after cessation of therapy. These well known facts concerning oral 
isotretinoin has been stated in several studies pointing on a 90 % efficacy of reducing 
sever inflammatory lesions(43).  
New questions brought in to light is weather an increased number of resistant PA 
actually have a significant impact on treatment outcome though the assessed studies 
proved different answers to this question. While resistant strains of PA may colonize 
the skin surface (even without causing acne), when skin samples are taken from acne 
patients, this sample does not measure the portion of resistant strains residing within 
the hair follicle, where the actual pathogenesis of acne take place. In studies, many 
times these skin samples are taken with a skin swab of the affected area. Unless the 
skin sample clearly is reflecting the number of resistant strains of PA residing in the 
hair follicle, one cannot really state weather the treatment outcome is associated with 
this number of resistant PA. Though antibiotics and topical retinoids work in an anti-
inflammatory fashion they indirectly inhibits PA way of action. This might be the 
explanation in Study I, were the number of tetracycline-resistant PA’s increased 
during the therapy as expected but did not affect the treatment outcome, expressed as 
total number of inflammatory lesions.   
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According to Tan et al (2003) it makes sense to state that an increased number of 
resistant strains contribute to more treatment failures. However PA that are resistant 
in vitro might not be the case in vivo(7, 44). So, does an increased number of 
resistant PA’s contribute to acne, and is this factor significantly affecting and 
correlating to the treatment outcome? Reflecting the large spectra of studies assessing 
this outcome, the answer is certainly yes, there is a correlation.  
The quality of evidence across studies was diverse for the three assessed outcomes. 
The main reason for the prevalent low evidence in two of the outcomes was the 
process of randomization and lack of blinding participants and clinicians. However it 
is reasonable to think it was difficult to make a proper masking with no ethical 
conflict. In the study were oral isotretinoin was given, adverse effects are more 
apparent and females had to take oral contraceptives. Though it is important for those 
taking oral isotretinoin not to get pregnant during therapy, it is obvious that it was not 
ethical to blind the patients. There was some inconsistency across studies when 
assessing the outcome of tetracycline resistant PA to oral tetracycline. Especially two 
studies had a different way of direction concerning their PA resistance and treatment 
effect outcome, contributing to the lack of consistency throughout studies. 
Limitations 
As for limitations in this review there are several aspects to discuss. At the outcome 
level the main limitations are that in the studies reviewed, the methods of 
randomization, grading of acne severity and the regimens were different across 
studies. Only one study compared oral tetracycline alone versus another antibiotic. 
Monotherapy comparisons were highly preferred but appeared to be a rare study 
intervention though most of studies compared combination therapies.  
 
There are several weaknesses related to the study and review level. There was a small 
sample of remaining studies assessed, though the search did not generate numerous 
high quality studies. Of those remaining, 3 of them were RCT studies, however none 
of them used placebo control groups. As for the quality of evidence it were in average 
low to moderate across studies for each outcome, which makes it difficult to make 
any general definite conclusions more than what is already stated in the present 
literature. Another limitation is that the studies did not provide all their data with 
effect measures with confidence intervals. Making it hard to draw conclusions and 
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compare the results. As for the reviewing it is possible that publication bias might 
have occurred for one study where the results was very vaguely presented compared 
to the other studies. Only two studies with the highest evidence stated that their 
analysis was in an intention-to-treat analysis. It is possible that an overestimation of 
the result is made in the study, which did not have this as an objective. Only one 
study provided calculations on number of participants that had to be in each control 
group to produce a statistical power. Limitations related to the search strategy could 
be that only studies published in the English language were selected and only those 
published in full-text. As for the inclusion and eligibility criteria, one might have 
produced a study selection to review not generally representative to the general 
population. Strengths of this review are the systematic manner of the reviewing due 
to the PRISMA statement, Cochrane working group and HTA-centrum(25, 31, 35).     
Conclusions and Implications 
Oral tetracycline is clearly an effective treatment in moderate to severe acne vulgaris, 
even more effective in the combination with topical retinoids. Topical therapy with 
retinoids and antimicrobials have similar efficacy as oral tetracyclines. The reason for 
this might be originating from the anti-inflammatory effect, which they all provide. 
There are other treatments that may promise better efficacy, however at the cost of 
more adverse effects. It is important to stress the fact that resistant strains of PA are 
increasing and that long term treatment with oral tetracycline’s, especially with 
lacking compliance selects resistant strains, which in turn may transfer resistance to 
other bacteria for example coagulase negative staphylococci (CNS). In this way, 
making it difficult to treat simple infections with the most commonly used antibiotics, 
it is a relevant subject to emphasize. The most important group to acknowledge these 
facts may be the general practitioners, which are the category of clinicians that most 
often treat these cases. There is a general misunderstanding that acne is something 
naturally that you have to accept. However this is not always the case. Patients 
presenting with acne should be taken seriously though there is an evident correlation 
between assessed quality of life and the severity of acne. To evaluate the efficacy of 
oral tetracycline and the impact of the number of tetracycline-resistant PA, further 
research is recommended comparing oral tetracycline versus other acne therapy in 
monotherapy.   
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Populärvetenskaplig sammanfattning 
Akne är en mycket vanlig hudsjukdom som drabbar upp emot 80 % av alla ungdomar. 
Uppkomsten är beroende av flera faktorer och består av en ökad talgproduktion, igen- 
proppning av talgkörtelns utförsgång på huden, ökat antal 
bakterier(Propionibacterium Acnes) och inflammation. Akne kan ses som svarta 
pormaskar och varfyllda finnar i ansikte och ibland på bålen som kan bli 
inflammerade. Akne indelas efter svårighetsgrad och det är också efter denna 
indelning den behandlas. Från den lättaste behandlingen ofta beståendes av lokala 
krämer som verkar på översta hudlagret eller mot bakterier till tablettbehandling med 
antibiotika och i de värsta fallen med det mycket potenta läkemedlet Roaccutan. Med 
den ökade användningen av antibiotika sållas motståndskraftiga bakterier fram mot 
de vanligaste antibiotikagrupperna som används vid akne.  
Förstahandsvalet vid måttlig till svår akne är tablettbehandling med 
antibiotikagruppen tetracykliner. Antibiotika läker inte ut akne utan verkar 
antiinflammatoriskt och på bakteriens tillväxt medan Roaccutan har förmågan att helt 
läka ut akne, dock med en risk för fler och svårare biverkningar.  
I denna systematiska litteraturöversikt behandlas ämnet tablettbehandling med 
antibiotika och dess effekt och biverkningar i behandling av akne. Då vetenskapen 
ligger till grund för val av behandling är det viktigt att behandlare har tillgång till en 
överblick av kunskapsläget och kan använda sig av den i sin klinik. Behovet av 
kritisk granskning av publicerade vetenskapliga artiklar är stort då en behandling kan 
stå emot en annan där klarheten för ett visst resultat inte alltid är värderad utifrån 
studiens metod och risk för felberäkningar. I denna systematiska litteraturöversikt 
undersöktes tre studier med hög trovärdighet avseende behandling med tetracykliner 
och annan vanlig aknebehandling.  
Slutsatsen är att många av de läkemedel som kan användas lokalt som krämer eller 
lösningar på huden som verkar mot bakterier vid akne är lika effektiva som 
tablettbehandling med antibiotika(tetracykliner). Det potenta läkemedlet Roaccutan är 
mycket mer effektiv än all annan aknebehandling men ger också fler biverkningar. 
Motståndskraft av bakterien Propionibacterium Acnes har en negativ inverkan på 
behandlingsresultatet.  
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A total of 95 studies were at first provided. After duplicates were removed 59 studies remained. 48 
studies were excluded when assessed in title and abstract for meeting inclusion criteria. 11 studies 
were assessed in full text for eligibility resulting in exclusion of 8 studies. Finally 3 studies were 
included in the qualitative analysis.  
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Outcome variable 1: Efficacy evaluation of oral tetracycline group vs. control treatment in acne vulgaris  
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*  + No problem  
    ? Some problems 
    - Major problems
Oprica et al., 2007 Sweden RCT, 
parallell-
group 
52 13 N=26, Tetracycline plus 
Adapalene. 
Improvement was seen 
(p<0.001), not as high 
efficacy as in control group 2. 
A swing up of lesions in the 
follow up period.  
N=26, Oral Isotretinoin  
More effective than control 1 in 
the majority of lesions, faster 
onset of action. Better efficacy 
than control 1 in the long term 
(p=0.009).  
Tetracycline 500mg 1x2. Topical 
adapalene 0.1 % once a day.  
Oral isotretinoin 1mg/kg/day in 2 
divided doses. Treatment for 24 weeks 
with a 2 month follow-up(control 1 
received adapalene under the 2 month 
follow-up period). 
- ? + 
Rafiei et al., 2006 Iran RCT, 
parallell-
group 
290 54 N=118, Tetracycline 
31.4% showed good/excellent 
results after 3 months.  No 
statistically significant 
difference in clinical response
compared to control 2 after 3 
months. p>0.05 
N=118, Azitromycin 
44% showed good/excellent 
results after 3 months. 
Degree of improvement was 
greater compared to control 1. 
Tetracycline 1g/day for 1 month, 
thereafter 500mg/day for 2 months. 
Azitromycin pulse- 500mg/day for 3 
consecutive days/week for 4 weeks. 
Afterwards azitromycin 250mg every 
other day for 2 months. After 1 month, 
topical tretinoin 0.05% was added to 
both groups. 
+ ? - 
Ozolins et al., 2004 
 
 
 
UK RCT 
Regimen 
1(R1) vs. 
regimen 4 
(R4) 
258 102 N=131, Oxytetracycline + 
topical placebo (Regimen 1) 
Efficacy between control 1 
and 2 were similar. 55% had 
moderate to great 
improvement at 18 weeks.  
N=127, Oral placebo + topical 
erythromycin in combo with 
benzoyl peroxide (Regimen 4) 
66% hade moderate tog great 
improvement at 18 weeks.  
Odds ratio, (95% CI) control 2 
versus control 1 is 1.64 (0.98-
2.74).  
R1: Oxytetracycline 500mg 1x2 + 
topical placebo twice a day.  
R4: Oral placebo once a day + topical 
3% erythromycin in combo with 5% 
benzoyl peroxide twice daily.  
Treatment for 18 weeks. 
+ + + 
Table displaying efficacy of oral tetracycline versus different acne treatments. Oprica et al compared oral tetracycline plus topical adapalene vs oral isotretinoin for 24 weeks. Oral isotretinoin was 
more effective in the majority of lesions with a better efficacy than the tetracycline plus adapalene group. Rafiei et al compared oral tetracycline versus oral azithromycin for 3 months, thereafter 
topical tretinoin in both groups for 1 month. There was a greater improvement of lesions in the azithromycin group, however there was no statistically significant difference in the clinical response. 
Ozolins et al compared oral oxytetracycline plus topical placebo (control 1) versus oral placebo plus topical erythromycin plus benzoyl peroxide (control 2) for 18 weeks. The efficacy between both 
groups was similar with odds ratio (95% CI) control 2 versus control 1 was 1.64 (0.98- 2.74).  
RCT: Randomized Controlled Trial, R1: Regimen 1, R4: Regimen 4 
 
Outcome variable 2: Side effects evaluation of oral tetracycline group vs. control treatment in acne vulgaris 
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*  + No problem  
    ? Some problems 
    - Major problems 
Oprica et al., 2007 Sweden RCT, 
Parallell-
group 
52 13 N=26, Tetracycline plus 
adapalene. 
10% complained of 
transitory nausea or 
abdominal pain. 15% 
experienced dry skin, 
itching and redness of the 
skin at one point during the 
24 weeks.  
N=26, Oral Isotretinoin 
Side effects: dry skin 91.4 %, 
chelitis 95.8%, dry eyes 75%, 
epitaxis 54% after 2 months of 
therapy. After discontinuation 
of therapy side effects 
disappeared in 83%.  
Most had transitory increase in 
triglycerides and cholesterol, 
although within normal range. 
Tetracycline 500mg 1x2. Topical 
adapalene 0.1 % once a day.  
Oral isotretinoin 1mg/kg/day in 2 
divided doses.  
Treatment for 24 weeks with a 2-
month follow-up (control 1 received 
adapalene under the 2 month follow-
up period). 
- ? + 
Rafiei et al., 2006 Iran RCT, 
Parallell-
group 
290 54 N=118, Tetracycline 
6.8% complained of of 
epigastric pain, 4.2 % 
complained of diarrhea, 
2.5% complained of 
vulvovaginal pruritus. 
In summary: 11% gastro 
intestinal side effects.  
N=118, Azitromycin 
5% complained of heartburn 
and epigastric pain, 5.9 % 
complained of diarrhea. 
 
In summary: 10.9% 
gastrointestinal side effects.  
Tetracycline 1g/day for 1 month, 
thereafter 500mg/day for 2 months.  
Azitromycin pulse- 500mg/day for 3 
consecutive days/week for 4 weeks. 
Afterwards Azitromycin 250mg every 
other day for 2 months. 
After 1 month, topical tretinoin 0.05% 
was added to both groups. 
+ ? - 
Table displaying side effects evaluation of oral tetracycline group versus different acne treatments. Oprica et al compared oral tetracycline plus topical adapalene (control 1) to oral isotretinoin (control 
2) for 24 weeks of treatment. Control 1 in Oprica et al experienced typical side effects produced by oral antibiotics such as gastrointestinal upset. Out of the 26 participants in this group 15 % 
experienced dry skin, itching and redness. Control 2 in Oprica et al experienced more side effects than control 1. The most common complaint was dry skin produced in 91.4 %, chelitis and dry eyes. 
These side effects disappeared in most cases after cessation of therapy. Most of the patients in control 2 had a transitory increase in lipid levels, however within the normal range.  
Rafiei et al compared oral tetracycline (control 1) to oral azithromycin (control 2) for 3 months with topical tretinoin for 2 months after 1 month of oral therapy in both groups. Both groups 
experienced similar gastrointestinal side effects at an equal amount.  
RCT: Randomized Controlled Trial 
 
 
 
Outcome variable 2: Side effects evaluation of oral tetracycline group vs. control treatment in acne vulgaris 
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*  + No problem  
    ? Some problems 
    - Major problems 
Ozolins et al., 2004 UK RCT 
Regimen 1 
vs. regimen 
4 
 
258 102 N=131, Oxytetracycline + 
topical placebo (Regimen 1)
Adverse events: After 
6weeks 22 patients 
experienced GI upset, 11 
CNS symptoms, 5 skin 
irritation.   
 
More systemic side effects 
compared to control 2.  
Control 1 and 2 had similar 
mean- patient- assessed –
irritation score. 
N=127, Oral placebo + topical 
erythromycin in combo with 
benzoyl peroxide (Regimen4) 
Adverse events: After 6 weeks 
8 patients experienced GI upset,
4 CNS symptoms, 11 skin 
irritation.   
More skin irritation compared 
to control 1. 
 
R1: Oxytetracycline 500mg 1x2 + 
topical placebo twice a day.  
 
R4: Oral placebo once a day + topical 
3% erythromycin in combo with 5% 
benzoyl peroxide twice daily.   
 
Treatment for 18 weeks. 
 
Gastrointestinal symptoms: nausea, 
upset stomach. 
CNS symptoms: Headache 
+ + + 
Table displaying side effects evaluation of oral tetracycline group versus different acne treatments continuation. Ozolins et al compared oral oxytetracycline plus topical placebo (control 1) to oral placebo 
plus topical erythromycin plus benzoyl peroxide (control 2) for 18 weeks. There were more systemic side effects in control 1 compared to control 2. Control 2 produced more skin irritation compared to 
control 1. Both groups had similar mean-patient-assessed- irritation score.  
 
RCT: Randomized Controlled Trial, R1: Regimen 1, R4: Regimen 4 
 
 
 
 
 
Outcome variable 3: Evaluation of Propionibacterium acnes resistance to oral tetracycline group vs. control treatment in acne vulgaris 
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  + No problem  
    ? Some problems 
    - Major problems 
 
Oprica et al., 2007 Sweden RCT, 
Parallel-
group 
52 13 N=26, Tetracycline plus 
adapalene. 
Higher probability of gaining 
clindamycin/tetracycline 
resistant PA’s after the 
follow-up 
N=26, Oral isotretinoin  
Patients with resistant PA are 
treated with ISO kept the 
already existing resistant strains 
or lost them. 
Tetracycline 500mg 1x2. Topical 
adapalene 0.1 % once a day.  
Oral isotretinoin 1mg/kg/day in 2 
divided doses.  
24 weeks therapy with a 2-month 
follow-up (control 1 received 
adapalene under the 2 month follow-
up period). 
- ? + 
Ozolins et al., 2004 
 
 
 
 
 
 
UK RCT 
Regimen 1 
vs. regimen 
4 
 
258 102 N=131, Oxytetracycline + 
topical placebo (Regimen 1)  
47% of patients colonized 
with resistant strains reported 
moderately improvement at 18
weeks compared to 56% that 
had no resistant strains to 
tetracycline.  
Reduction in mean skin lesion 
count at 18 weeks was 
significantly less effective for 
control 1 versus control 2 for 
those with resistant strains. 
23.1(11.8-34.5) 
N=127, Oral placebo + topical 
erythromycin in combo with 
benzoyl peroxide (Regimen 4)  
48% was colonized at baseline 
with erythromycin-resistant 
PA’s. A reduction of 9 % in 
number of colonized 
participants was seen after 18 
weeks.  
Topical erythromycin gave the 
largest reduction (16%) in 
population of all PA strains 
after 18 weeks.  
R1: Oxytetracycline 500mg 1x2 + 
topical placebo twice a day.  
R4: Oral placebo once a day + topical 
3% erythromycin in combo with 5% 
benzoyl peroxide twice daily.   
Treatment for 18 weeks. (Measured as 
effect of colonization with 
tetracycline-resistant PA’s on 
treatment outcome).  
Simplification: A significantly 
decreased effect of therapy with 
oxytetracycline was seen in 
participants colonized with 
tetracycline resistant PA’s strains.  
+ + + 
Table displaying evaluation of Propionibacterium acnes resistance to oral tetracycline group versus other treatment in acne. In Oprica et al they compared oral tetracycline plus topical adapalene (control 
1) to oral isotretinoin (control 2) for 24 weeks of treatment. In control 1 in Oprica et al there was a higher probability of gaining clindamycin and tetracycline resistant PA’s after the follow-up. However 
in control 2 in Oprica et al those who already had resistant PA kept the resistant strains or lost them.                                                                                                                                                                
Ozolins et al compared oral oxytetracycline plus topical placebo (control 1) to oral placebo plus topical erythromycin plus benzoyl peroxide (control 2) for 18 weeks. In control 1 in Ozolins et al, those 
that had no resistant strains to tetracycline reported moderately improvement to a higher extent compared to participants colonized with resistant strains. Reduction in mean skin lesion count was 
significantly less effective in control 1 compared to control 2, 23.1 (11.8- 34.5). There was a significantly decreased effect of therapy with oral oxytetracycline in participants colonized with tetracycline 
resistant PA’s.  
 RCT: Randomized Controlled Trial, R1: Regimen 1, R4: Regimen 4, PA: Propionibacterium acnes 
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           GRADE analyse 
 
         
Side effects of 
tetracycline vs. other 
regimen 
          
 
3 
 
RCT  
 
 
 
No serious 
limitations 
(0) 
 
No important 
inconsistency 
 
No uncertainty 
 
 
No Imprecision 
 
Unlikely 
 
Not 
relevant 
Not 
analysed 
Not 
analysed 
Moderate 
 
Efficacy of 
tetracycline vs. other 
regimen 
          
3 RCT 
Serious 
limitations (-
1) 
Some 
inconsistency 
(0?) 
Some uncertainty 
(0?) 
Uncertain 
precision (0?) Unlikely 
Not 
relevant 
Not 
Statistically 
significant
Not 
analysed 
Low 
 
 
Evaluation of 
resistant PA’s in 
therapy with oral 
tetracycline vs. other 
treatment 
          
2 RCT 
No serious 
limitations 
(0) 
Very serious 
inconsistency 
(-2) 
Serious 
indirectness (-1) 
Uncertain 
precision (0?) Unlikely 
Not 
relevant 
Not 
Statistically 
significant
Not 
analysed 
Low 
 
Evidence through out studies assessed for each outcome measure. Side effects of tetracyclines versus other regimen had a moderate evidence grade. Efficacy of 
tetracyclines versus other regimens provided low evidence. There was a low evidence concerning evaluation of the PA’s resistance. 
 
 
 
44
       Exclusion Table 
 
         Providing studies that were excluded and the reason for exclusion.
 
Study 
(Author, publication year) 
Reason for exclusion 
 
 
Khorvash et al., 2012 Case-Control study. 
Leyden et al., 2011 
 
Intervention not concurrent with PICO. 
Purdy et al., 2011 
 
Review. 
Lipozenic et al., 2011 
 
Not concurrent with PICO (perioral dermatitis) 
Yoon et al., 2010 
 
Not concurrent with PICO (Stevens-Johnson Syndrome) 
Jang et al., 2010 
 
Case study. 
Ochsendorf et al., 2010 
 
Review. 
Geddes et al., 2010 
 
Intervention not concurrent with PICO. 
Sugita et al., 2010 
 
Not concurrent with PICO. (Antifungals) 
Del Rosso JQ et al., 2009 
 
Review. 
Purdy et al., 2008 
 
Review. 
Simonart et al., 2008 
 
Review. 
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Guay et al., 2007 
 
Review. 
 
Tehrani et al., 2007 
 
Case study. 
 
Benjamin et al., 2007 Case-control study. 
Somani et al., 2006 
 
Case study. 
Ochsendorf et al., 2006 
 
Review. 
Friedman et al., 2005 
 
Review. 
Tan et al., 2004 
 
Review. 
Mouton et al., 2004 
 
Not concurrent with PICO. 
Bikowski et al., 2003 
 
Review. 
Tan et al., 2003 
 
Review. 
Garner et al., 2003 
 
Review. 
Moon et al., 2012 
 
Intervention not concurrent with PICO. 
Song et al., 2011 
 
Intervention not concurrent with PICO. 
Gonzalez et al., 2011 
 
Intervention not concurrent with PICO. 
Hassanzadeh et al., 2008 
 
Intervention not concurrent with PICO. 
 
Margolis et al., 2007 
 
Participants and outcome not concurrent with PICO. 
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Del Rosso et al., 2006 Review. 
Van Zuuren EJ et al., 2011 
 
Subject not of interest. (Rosacea) 
Arowojolu et al., 2012 
 
Subject not of interest. (Oral contraceptives) 
Thevarajah et al., 2005 
 
Observational study. 
Adawiyah et al., 2010 
 
Observational study. 
Tan et al., 2005 Review. 
Shalita et al., 2012 
 
Intervention not concurrent with PICO. 
Wainwright et al., 2012 
 
Intervention not concurrent with PICO. 
Holst et al., 2011 
 
Case study. 
Leyden et al., 2011 
 
Review. 
Ingram et al., 2010 
 
Review. 
Geria et al., 2009 
 
Intervention not concurrent with PICO. 
Branley et al., 2009 
 
Case study. 
Tabibian et al., 2009 
 
Case study. 
Amin et al., 2007 
 
Review. 
Riddle et al., 2007 
 
Review. 
Webster et al., 2007 
 
Review. 
Rao et al., 2006 
 
Review. 
 
No author name available, 
2006 
 
Intervention not concurrent with PICO. 
 
 
 47 
Kinney et al., 2010 
 
Observational study. 
Owczarek W Fau et al., 2011 
 
Review. 
Kircik LH., 2010 
 
Review. 
Ochsendorf F., 2010 
 
Review. 
Adisen E Fau-Kaymak et al., 2008 
 
Intervention not concurrent with PICO. 
Song SJ., 2007 
 
Subject not of interest. (Ear point blood-letting) 
Leyden Jj Fau et al., 2007 
 
Review. 
Ma Xh Fau-Zhu et al., 2004 
 
Subject not of interest. (Intervention with Qingre Cuochuang tablet) 
Del Rosso etal., 2007 
 
Review. 
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